Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Kyowa Hakko Licenses Antibody for Cancer Treatment
March 10, 2008
- Nucleic Acid-Based Drugs Will Be Innovative Drugs of Next Generation: Prof. Morishita
March 10, 2008
- Pfizer Japan Mobilizes All Employees, Officers to Defend Market for Norvasc
March 10, 2008
- GCP for Medical Devices to Be Amended
March 10, 2008
- TOPICS／Dr Karasawa Will Soon Be Back to Office: JMA
March 10, 2008
- Teijin's Gout Treatment TMX-67 Receives Approvable Letter in the EU
March 10, 2008
- Nippon Shinyaku Enters the Field of OB-GYN with IKH-01
March 10, 2008
- Kyowa Hakko Receives Not-Approvable Letter from FDA for Istradefylline
March 10, 2008
- Makers Should Propose Invoice Prices That Reflect Market Prices: Mr Hamada of Toho
March 3, 2008
- Korosho to Survey Measures Taken Overseas to Ensure Safety of Research Using iPS Cells
March 3, 2008
- Iberica Ready to Undertake PI Studies Simultaneously in both Japanese and Americans
March 3, 2008
- Daiichi Sankyo, Eli Lilly Apply for Prasugrel in EU
March 3, 2008
- Number of Privately-Operated Pharmacies to be Halved: Mr Urushibata
March 3, 2008
- New GL on Drugs Obtained from Autologous Cells Announced
March 3, 2008
- BUSINESS NEWS IN BRIEF
March 3, 2008
- STATISTICS／Rate of Death due to Liver Cancer Is Third Highest in Japan
March 3, 2008
- Pharmacies Will Lose or Win Depending on How Many Generics They Dispense
March 3, 2008
- Japan Needs to Introduce Medicoeconomic Assessment of Medical Technologies: Prof Kamae
March 3, 2008
- 50-60% of People Want to Use Generics: Survey
March 3, 2008
- REGULATORY NEWS IN BRIEF
March 3, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…